Andrew Obenshain, bluebird bio CEO
January 10, 2024 05:15 PM EST
Financing
Cell/Gene Tx

Blue­bird is still look­ing for more fi­nanc­ing as it brings sick­le cell ther­a­py to mar­ket: #JPM24

Drew Armstrong

Executive Editor

SAN FRAN­CIS­CO — Af­ter strik­ing deals for as much as $225 mil­lion in fi­nanc­ing, blue­bird bio’s CEO said the com­pa­ny is still on the look­out for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Evotec gains on Halozyme's takeover pro­pos­al

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

Eli Lil­ly sues the US gov­ern­ment over its pro­posed 340B re­bate mod­el

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times